KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Bionano Genomics (BNGO) Cash from Operations (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Cash from Operations for 9 consecutive years, with 4100000.0 as the latest value for Q4 2025.

Quarterly Cash from Operations rose 36.96% to 4100000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 16300000.0 through Dec 2025, up 76.35% year-over-year, with the annual reading at 16300000.0 for FY2025, 76.35% up from the prior year.
Cash from Operations hit 4100000.0 in Q4 2025 for Bionano Genomics, up from 5949000.0 in the prior quarter.
In the past five years, Cash from Operations ranged from a high of 2764000.0 in Q1 2025 to a low of 36696000.0 in Q2 2023.
Historically, Cash from Operations has averaged 20357300.0 across 5 years, with a median of 23300000.0 in 2021.
Biggest five-year swings in Cash from Operations: plummeted 133.7% in 2022 and later soared 90.17% in 2025.
Year by year, Cash from Operations stood at 25622000.0 in 2021, then tumbled by 34.72% to 34517000.0 in 2022, then rose by 13.73% to 29779000.0 in 2023, then surged by 78.16% to 6504000.0 in 2024, then soared by 36.96% to 4100000.0 in 2025.
Business Quant data shows Cash from Operations for BNGO at 4100000.0 in Q4 2025, 5949000.0 in Q3 2025, and 3487000.0 in Q2 2025.